Core Viewpoint - The approval of the listing application for Glycopyrrolate by the National Medical Products Administration marks a significant milestone for the company, enhancing its product portfolio in the pharmaceutical market [1] Group 1: Product Approval - The company's subsidiary, Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received the approval notice for the listing application of Glycopyrrolate on October 16, 2025 [1] - Glycopyrrolate is a quaternary ammonium anticholinergic drug that selectively acts on the gastrointestinal tract, inhibiting gastric secretion and adjusting gastrointestinal motility [1] - The drug can specifically bind to and inhibit the M3 acetylcholine receptors in bronchial smooth muscle, leading to airway dilation [1] Group 2: Product Forms - Glycopyrrolate is available in various formulations, including injection, inhalation powder, inhalation solution, oral solution, tablets, and a combination inhalation aerosol with Formoterol [1] - Some formulations, such as Glycopyrrolate injection and Glycopyrrolate/Formoterol inhalation aerosol, have been included in the medical insurance directory [1] Group 3: Sales Performance - In 2024, the hospital sales of Glycopyrrolate injection reached 53.5772 million yuan, representing a year-on-year growth of 38.29% [1] - In the first half of 2025, the hospital sales of Glycopyrrolate injection amounted to 37.407 million yuan, showing a significant year-on-year increase of 79.21% [1]